Symptomatic hypokalemia secondary to meglumine antimoniate [3];Hypokaliémie symptomatique secondaire à l'antimoniate de méglumine

Annales de Dermatologie et de Venereologie

Volumn 134, Issue 4, 2007, Pages 387-388

  Bouvresse, S ^a   Matichard, E ^a   Mahe E ^a   Marinho, E ^a   Soria, A ^a   Devilliere M ^a   Descamps, V ^a   Crickx, B ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDACTAZINE; ANTIMONY; MEGLUMINE; MEGLUMINE ANTIMONATE; RILMENIDINE;

ADULT; CASE REPORT; CLINICAL FEATURE; ELECTROCARDIOGRAPHY; FEMALE; HISTOLOGY; HUMAN; HYPERTENSION; HYPOKALEMIA; LETTER;

EID: 34248332489     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(07)89199-X     Document Type: Letter

References (5)

1. Masmoudi A, Maalej N, Mseddi M, Souissi A, Turki H, Boudaya S, et al. Glucantime injection: benefit versus toxicity. Med Mal Infect 2005;35: 42-5.
2. Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg 1988;82:69-72.
3. Castello Viguer MT, Echanove Errazti I, Ridocci Soriano F, Esteban Esteban E, Atienza Fernandez F, Cuesta Estelles G. Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate. Rev Esp Cardiol 1999;52:533-5.
4. Horber FF, Lerut J, Jaeger P. Renal tubular acidosis, a side effect of treatment with pentavalent antimony. Clin Nephrol 1991;36:213.
5. Rodrigues ML, Costa RS, Souza CS, Foss NT, Roselino AM. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev Inst Med Trop Sao Paulo 1999;41:33-7.